http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20030085361-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_319ac9d729dcf44fc0463b2d37d25e6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa0a8a718cac5315e779c640ffd410b4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10033 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-235 |
| filingDate | 2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bced27a1d93849ea247d70643d08df63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c11a7c67f75b161b7042bc6b913df79d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13731a8ccab009be72d04032062b30d0 |
| publicationDate | 2003-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20030085361-A |
| titleOfInvention | Tumor-Specific Replication Competent Recombinant Adenovirus with Enhanced Tumoricidal Effect Inducing Apoptosis |
| abstract | The present invention relates to adenoviruses having an improved tumor killing effect and capable of killing tumors specifically, and to pharmaceutical antitumor compositions comprising the same. More specifically, the expression of E1B 19 kDa protein and E1B 55 kDa protein of adenovirus may be reduced. It relates to a recombinant adenovirus and a pharmaceutical anti-tumor composition comprising the same to induce mutations in the E1B 19 and E1B 55 gene to be inhibited to induce tumor-specific cell necrosis and apoptosis at the same time, thereby improving the tumor-specific cell killing effect, The recombinant adenovirus of the present invention can specifically kill in cancer cells in which the function of the p53 protein, a tumor suppressor protein, is inhibited, and greatly improve tumor cell killing ability, thereby overcoming the limitations of the conventional method for treating tumors by recombinant adenovirus. And furthermore, the pharmaceutical compositions of the present invention When used in combination with cancer treatment methods of rats, in particular cancer treatment methods that induce cell death can maximize the therapeutic effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100749857-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007086631-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100749858-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100747646-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100746122-B1 |
| priorityDate | 2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.